<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Myeloablative conditioning continues to be employed in hematopoietic stem cell transplantation among patients with pediatric transplant indications </plain></SENT>
<SENT sid="1" pm="."><plain>Fractionated TBI (fTBI) remains, with its considerable anti-leukemic potential, the cornerstone of conditioning in the most common of pediatric indications, ALL in its first, second or subsequent remission despite its well-established long-term sequelae </plain></SENT>
<SENT sid="2" pm="."><plain>The feasibility of chemotherapy-only regimens has been established and these regimens widely employed in other pediatric indications, for example, in ALL below the age of 2 years, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:hpo ids='HP_0002863'>myelodysplasias</z:hpo> or severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Conditioning regimens are being modified with data accumulating on the role of, for example, pre-transplant <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual disease</z:e>, advanced HLA-typing or haploidentical transplantations in the pediatric setting </plain></SENT>
</text></document>